Axcella Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020
October 02 2020 - 7:58AM
Business Wire
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
pioneering a new approach to treat complex diseases and improve
health using endogenous metabolic modulator (EMM) compositions,
today announced two upcoming poster presentations at The Liver
Meeting® 2020, the Annual Meeting of the American Association for
the Study of Liver Diseases (AASLD), which is taking place
virtually November 13-16, 2020. These presentations will include
key data from the company’s AXA1125-003 clinical study, including
in subjects with type 2 diabetes as well as the overall study
population.
- Abstract 1663: “Biological Activity of AXA1125
and AXA1957 on Glucose, Insulin, HOMA-IR, and HbA1c and Measures of
Liver Fat and Fibroinflammation in a Prospective 16-Week
Randomized, Placebo-Controlled Study in Subjects with NAFLD and
Type 2 Diabetes”
- Abstract 1694: “Safety, Tolerability, and
Biological Activity of AXA1125 and AXA1957 in a Prospective 16-Week
Randomized, Placebo-Controlled Study in Subjects with NAFLD with
and without Type 2 Diabetes”
About Endogenous Metabolic Modulators (EMMs) EMMs are a
broad family of molecules, including amino acids, that regulate
human metabolism. Axcella is developing a range of novel product
candidates that are comprised of multiple EMMs engineered in
distinct combinations and ratios to simultaneously impact multiple
metabolic pathways to modify the root causes of various complex
diseases and improve health.
About Axcella’s Clinical Studies Each of the company’s
clinical studies to date are or have been conducted as
non-investigational new drug application (IND) clinical studies
under U.S. Food and Drug Administration regulations and guidance
supporting research with food. These studies evaluate product
candidates for safety, tolerability and effects on the normal
structures and functions in humans, including in individuals with
disease. They are not designed or intended to evaluate a product
candidate’s ability to diagnose, cure, mitigate, treat or prevent a
disease. If Axcella decides to further develop a product candidate
as a potential therapeutic, as is the case with AXA1665 and
AXA1125, any subsequent clinical studies will be conducted under an
IND.
Internet Posting of Information Axcella uses its website,
www.axcellahealth.com, as a means of disclosing material nonpublic
information and for complying with its disclosure obligations under
Regulation FD. Such disclosures will be included on the company’s
website in the “Investors and News” section. Accordingly, investors
should monitor this portion of the company’s website, in addition
to following its press releases, SEC filings and public conference
calls and webcasts.
About Axcella Axcella is a clinical-stage biotechnology
company pioneering a new approach to treat complex diseases and
improve health using endogenous metabolic modulator (EMM)
compositions. The company’s product candidates are comprised of
EMMs and their derivatives that are engineered in distinct
combinations and ratios to simultaneously impact multiple
biological pathways. Axcella’s pipeline includes lead therapeutic
candidates for non-alcoholic steatohepatitis (NASH) and the
reduction in risk of overt hepatic encephalopathy (OHE) recurrence.
Additional muscle- and blood-related programs are in earlier-stage
development. For more information, please visit
www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201002005068/en/
Jason Fredette jfredette@axcellahealth.com 857.320.2236
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024